Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer.
Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.
Journal: Blood cancer journal
Published: November 28, 2025
Can Posttransplant Cyclophosphamide Reduce Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft vs Host Disease Prevention?: A Multicenter Cohort Study.
Journal: Chest
Published: September 21, 2025
Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasms.
Journal: Leukemia research
Published: April 03, 2025
Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots.
Journal: Hematology reports
Published: March 21, 2025
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Journal: Leukemia
Published: March 19, 2025
Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis.
Journal: Bone marrow transplantation
Published: February 23, 2025
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Journal: American journal of hematology
Published: November 16, 2024
Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms.
Journal: Leukemia & lymphoma
Published: November 06, 2024
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms.
Journal: Leukemia
Published: June 16, 2024
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Journal: American journal of hematology
Published: November 24, 2023
Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study.
Journal: Bone marrow transplantation
Published: September 13, 2023
Last Updated: 09/26/2026